Evidence map›Paper›PMID 23861993›Full record

Trial reportOxidative medicine and cellular longevity2013

Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b.

V Ramirez-Ramirez, M A Macias-Islas, G G Ortiz, F Pacheco-Moises, E D Torres-Sanchez, T E Sorto-Gomez, J A Cruz-Ramos, G Orozco-Aviña, A J Celis de la Rosa

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Oxidative medicine and cellular longevity, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02939079 (Evaluating the Effect of Fingolimod With Fish Oil Compared to Fingolimod With Placebo on Tumor Necrosis Factor-α , Interleukin1b , Interleukin6, and Interferon-gamma in Patients With Relapsing-Remitting Multiple Sclerosis), which is not on this map. Cited by 72 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 8 pooled it
3.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02939079 phase2 / phase3completednot on this mapstarted 2015, after this paper: background citation

Evaluating the Effect of Fingolimod With Fish Oil Compared to Fingolimod With Placebo on Tumor Necrosis Factor-α , Interleukin1b , Interleukin6, and Interferon-gamma in Patients With Relapsing-Remitting Multiple Sclerosis

TypeinterventionalSponsorIsfahan University of Medical SciencesRan2015 to 2016Enrolled50ConditionsMultiple SclerosisArmsFingolimod, Fish Oil, Placebo (for Fish Oil)
3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 8 syntheses or guidelines pooled it, 119 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Dietary interventions for multiple sclerosis-related outcomes.The Cochrane database of systematic reviews · 2020
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

V Ramirez-RamirezLaboratorio de Mitocondria-Estrés Oxidativo & Patología, División de Neurociencias, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Sierra Mojada 800, 44340 Guadalajara, JAL, Mexico.
M A Macias-Islas
G G Ortiz
F Pacheco-Moises
E D Torres-Sanchez
T E Sorto-Gomez
J A Cruz-Ramos
G Orozco-Aviña
A J Celis de la Rosa
Mexican Social Security Institute · MXUniversidad de Guadalajara · MXHospital de Especialidades · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledMultiple sclerosis (MS) is a chronic inflammatory disease, which leads to focal plaques of demyelination and tissue injury in the central nervous system. Oxidative stress is also thought to promote tissue damage in multiple sclerosis. Current research findings suggest that omega-3 polyunsaturated fatty acids (PUFAs) such as eicosapenta-enoic acid (EPA) and docosahexaenoic acid (DHA) contained in fish oil may have anti-inflammatory, antioxidant, and neuroprotective effects. The aim of the present work was to evaluate the efficacy of fish oil supplementation on serum proinflammatory cytokine levels, oxidative stress markers, and disease progression in MS. 50 patients with relapsing-remitting MS were enrolled. The experimental group received orally 4 g/day of fish oil for 12 months. The primary outcome was serum TNF α levels; secondary outcomes were IL-1 β 1b, IL-6, nitric oxide catabolites, lipoperoxides, progression on the expanded disability status scale (EDSS), and annualized relapses rate (ARR). Fish oil treatment decreased the serum levels of TNF α , IL-1 β , IL-6, and nitric oxide metabolites compared with placebo group (P ≤ 0.001). There was no significant difference in serum lipoperoxide levels during the study. No differences in EDSS and ARR were found.

conclusionFish oil supplementation is highly effective in reducing the levels of cytokines and nitric oxide catabolites in patients with relapsing-remitting MS.

Indexed as

AdultAnimalsFemaleHumansInterferon-betaInterferon beta-1bInterleukin-1betaInterleukin-6MaleMultiple SclerosisOxidative StressTumor Necrosis Factor-alphaInterferon-betaInterferon beta-1bInterleukin-1betaInterleukin-6Tumor Necrosis Factor-alpha

Identifiers

PMID23861993
PMCPMC3703725
OpenAlexW1963714104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.